Featured Research

from universities, journals, and other organizations

Cetuximab Increases Survival In Advanced Colorectal Cancer Patients

Date:
April 19, 2007
Source:
American Association for Cancer Research
Summary:
Research presented at the 2007 Annual Meeting of the American Association for Cancer Research confirmed that there is now an effective treatment option for colorectal cancer patients for whom all other treatment options have been exhausted -- cetuximab.

Research presented at the 2007 Annual Meeting of the American Association for Cancer Research confirmed that there is now an effective treatment option for colorectal cancer patients for whom all other treatment options have been exhausted -- cetuximab.

In a study of 572 colorectal cancer patients, researchers in Canada, Australia, New Zealand and Singapore found that cetuximab, marketed under the brand-name Erbitux®, improved survival time and slowed progression of the disease. Support for the study was provided by Bristol-Myers Squibb Company and ImClone Systems Incorporated.

"Cetuximab improved survival in these patients when all other therapies had failed," said Derek Jonker, M.D., assistant professor at the University of Ottawa and Canadian co-chair of the study. "This is the first time a single agent biologically targeted therapy has demonstrated a survival advantage in patients with colorectal cancer, and it is also the first time an EGFR-targeting drug has achieved this goal."

Conducted by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) in collaboration with the Australasian Gastro-Intestinal Trials Group (AGITG), the study, called CO.17, was a randomized, multi-center, phase III trial. It compared cetuximab plus best supportive care to best supportive care alone in patients with metastatic colorectal cancer whose disease was no longer responding to all available chemotherapy, including irinotecan, oxaliplatin and fluoropyrimidines.

The goal of the CO.17 study was to evaluate the effect of cetuximab on survival in patients with advanced colorectal cancer who are without other options for treatment other than supportive care.

Study participants were randomly selected either to receive best supportive care alone, or best supportive care plus cetuximab intravenously weekly until the cancer progressed further. According to Jonker, the researchers defined best supportive care as any and all care given to alleviate symptoms of the cancer and to improve quality of life. The participants who were to receive cetuximab were given 400 mg of the drug intravenously at the outset of the trial, followed by weekly doses of 250 mg.

Cetuximab, an antibody against the epidermal growth factor receptor (EGFR), functions by binding to the receptor on the surface of cancer cells. This binding action prevents the activation of enzymatic pathways that lead to cell growth and proliferation. Cetuximab also enlists the body's immune system triggering "natural killer cells" to attack the cancer, a process called antibody dependent cell cytotoxicity.

Jonker and his colleagues followed the patients, assessing the status of the tumors every eight weeks by CT scan until the cancer began to progress. According to Jonker, the results of the CO.17 trial showed a statistically significant 23 percent improvement in overall survival (the primary outcome being studied) as well as a 32 percent reduction in the risk of disease progression (the secondary outcome being studied). The survival time of the participants was, on average, six months for the patients given cetuximab versus four-and-a-half months for patients who received best supportive care alone.

"Earlier studies demonstrated cetuximab could shrink colon tumors, both alone and when combined with chemotherapy," Jonker said. "While some patients receiving cetuximab in the CO.17 study had significant tumor shrinkage, many more had the cancer growth arrested, delaying progress of the disease and resulting in patients living longer."

"These promising results," Jonker said, "will lead to further National Cancer Institute of Canada trials in which cetuximab will be combined with other therapeutics to treat metastatic colorectal cancer."


Story Source:

The above story is based on materials provided by American Association for Cancer Research. Note: Materials may be edited for content and length.


Cite This Page:

American Association for Cancer Research. "Cetuximab Increases Survival In Advanced Colorectal Cancer Patients." ScienceDaily. ScienceDaily, 19 April 2007. <www.sciencedaily.com/releases/2007/04/070416150159.htm>.
American Association for Cancer Research. (2007, April 19). Cetuximab Increases Survival In Advanced Colorectal Cancer Patients. ScienceDaily. Retrieved August 2, 2014 from www.sciencedaily.com/releases/2007/04/070416150159.htm
American Association for Cancer Research. "Cetuximab Increases Survival In Advanced Colorectal Cancer Patients." ScienceDaily. www.sciencedaily.com/releases/2007/04/070416150159.htm (accessed August 2, 2014).

Share This




More Health & Medicine News

Saturday, August 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Quintuplets Head Home

Texas Quintuplets Head Home

Reuters - US Online Video (Aug. 1, 2014) — After four months in the hospital, the first quintuplets to be born at Baylor University Medical Center head home. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Patient Coming to U.S. for Treatment

Ebola Patient Coming to U.S. for Treatment

Reuters - US Online Video (Aug. 1, 2014) — A U.S. aid worker infected with Ebola while working in West Africa will be treated in a high security ward at Emory University in Atlanta. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Vaccine Might Be Coming, But Where's It Been?

Ebola Vaccine Might Be Coming, But Where's It Been?

Newsy (Aug. 1, 2014) — Health officials are working to fast-track a vaccine — the West-African Ebola outbreak has killed more than 700. But why didn't we already have one? Video provided by Newsy
Powered by NewsLook.com
Study Links Certain Birth Control Pills To Breast Cancer

Study Links Certain Birth Control Pills To Breast Cancer

Newsy (Aug. 1, 2014) — Previous studies have made the link between birth control and breast cancer, but the latest makes the link to high-estrogen oral contraceptives. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins